Abstract

Purpose: Microsatellites are not amenable for high-throughput genotyping and have been excluded from GWAS. However, several microsatellites have been found to affect expression of nearby genes and a couple of them, in the asporin and BMP5 genes, have been associated with susceptibility to OA in multiple studies. In a recent exploration of functional microsatellites we found association of the -794 CATT microsatellite in the MIF gene with hip OA in 1782 patients compared with 1878 healthy controls of European ancestry. Replication in other patient collections was hampered by the lack of a method to obtain the genotypes without actually performing the laboratory tests. Therefore, we aimed to develop an imputation methodology for this microsatellite using the genotypes of SNPs in linkage disequilibrium and to apply it for validation. Methods: In our previous study of the MIF microsatellite, we had included 1090 samples that were also in the arcOGEN GWAS. Genotypes of the 130 SNPs in the linkage disequilibrium region surrounding the microsatellite in these samples were used as source of haplotype information. Imputation was done with Impute2 with modifications allowing estimation of the probabilities for the number of copies of each microsatellite allele and their posterior combination. Performance of this procedure was evaluated in 10 replicates of training, with 90 % of the samples, and testing of accuracy in the remaining 10 % of the samples with known microsatellite genotypes. Once concordance of imputed genotypes with tested genotypes was established, the approach was applied for the imputation of the MIF microsatellite in 5667 population controls from Wellcome Trust Case-Control Consortium (WTCCC) and in 2466 hip OA cases from arcOGEN (all of them of European UK ancestry). In addition, we have validated the functional effect of the MIF microsatellite on the plasma levels of MIF in 361 healthy control samples by ELISA (R&D Systems) from subjects that were either homozygous for the 5 repeat or the 6 repeat alleles. MIF microsatellite allele frequencies were compared with POWERMARKER and differences in plasma levels of MIF were analyzed with ANOVA using Statistica 7.0 (StatSoft). Results: There was a microsatellite allele with frequency lower than 1% that was not included in the imputation. The genotypes of the other three alleles were imputed with sufficient accuracy (91.6 %) and call rate in the reference samples (98.8). However, other microsatellites showed that the procedure will require further refinements to attain this performance for microsatellites with more alleles. Application of this procedure to the WTCCC and arcOGEN samples produced genotypes for 99.0 % of the samples. Comparison of the allelic frequencies showed significant differences between hip OA and controls in women (Table 1) following the same pattern found in our previous study, with the five repeats allele less frequent in the patients than in the controls (OR = 0.88, [95% CI] 0.79 to 0.98, P = 0.018). However, no difference was appreciated in men or between control women and men as it was in our previous study. This contrast between studies could be attributed to the use of OA-free controls in the previous study and population controls here. Analysis of MIF in plasma of healthy controls showed higher levels in the homozygous for the 5 repeat allele (3.6 ng/mL) than for the 6 repeat allele (2.7 ng/mL; P = 0.00025) following the direction previously reported by other authors and without differences between women and men. Conclusions: A new method to impute genotypes of microsatellites with three alleles based on SNP genotypes has been developed. It has shown good call rate and accuracy. This procedure allowed us to validate the association of the MIF microsatellite with hip OA in a large number of cases and controls. Concordance with our previous study was obtained in women, but not in men. Higher MIF levels were found in the subjects with the hip OA protective allele. These results should contribute to define the role of MIF, an important cytokine, in the OA pathology.Tabled 1Comparison of the allele frequencies of the MIF microsatelliteControlsTHRWomenMenWomenMenAlleleCountFreqCountFreqCountFreqCountFreq5140225.4143925.367123.147424.36345362.5357462.7185363.7123763.5766912.168512.038613.323712.2Total5524569829101948 Open table in a new tab

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.